BG
BPMC

Bellevue Group’s Blueprint Medicines BPMC Stock Holding History

Bellevue Group’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-284,900
Closed -$36.5M – 153
2025
Q2 		$36.5M Buy
+284,900
New +$29.6M 0.8% 32
2025
Q1 		– Sell
-3,200
Closed -$279K – 152
2024
Q4 		$279K Hold
3,200
– – 0.01% 139
2024
Q3 		$296K Sell
3,200
-1,900
-37% -$189K ﹤0.01% 139
2024
Q2 		$550K Hold
5,100
– – 0.01% 126
2024
Q1 		$484K Buy
+5,100
New +$437K 0.01% 131
2022
Q2 		– Sell
-26,000
Closed -$1.66M – 175
2022
Q1 		$1.66M Buy
26,000
+500
+2% +$35.9K 0.02% 138
2021
Q4 		$2.73M Buy
+25,500
New +$2.67M 0.03% 140
2020
Q1 		– Sell
-20,200
Closed -$1.62M – 220
2019
Q4 		$1.62M Buy
20,200
+4,400
+28% +$329K 0.03% 137
2019
Q3 		$1.16M Buy
15,800
+300
+2% +$25.9K 0.02% 140
2019
Q2 		$1.46M Buy
+15,500
New +$1.28M 0.03% 136

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Bellevue Group's BPMC Position: Q3 2025 in Review

Bellevue Group sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 284,900 shares — an estimated $36.5M sold.

Bellevue Group first reported a position in BPMC in Q2 2019 and held it in 10 quarters. The position peaked at $36.5M in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Bellevue Group reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Bellevue Group sold 284,900 Blueprint Medicines shares in Q3 2025, an estimated $36.5M.
  • Bellevue Group first reported a position in Blueprint Medicines in Q2 2019 and held it in 10 quarters.
  • Bellevue Group's Blueprint Medicines position peaked at $36.5M in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Bellevue Group's 13F filing for Q3 2025, filed 14 Nov 2025.